Currentsierra health and lifePolicy 2026T0560KK

Cell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy (PDF) PDF Opens in new windowopens in a new tabopens in a new window

UnitedHealthcare Commercial and Individual Exchange medical policy governing coverage and medical necessity criteria for cell-free fetal DNA (cfDNA) testing during pregnancy, including RhD genotyping, screening for common trisomies, sex chromosome aneuploidies, rare autosomal trisomies, microdeletions/CNVs, expanded/genome-wide testing, and related indications. This part (1 of 3) includes coverage rationale, definitions, applicable codes, evidence summaries, and limits on use.

Policy Summary

Payersierra health and life

PolicyCell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy (PDF) PDF Opens in new windowopens in a new tabopens in a new window

Policy CodePolicy 2026T0560KK

Change TypeTemplate Update; archived prior versions

Effective DateJanuary 1, 2026

Next Review Date

Key ActionDocument that indicated invasive diagnostic testing (e.g., amniocentesis or CVS) for fetal genotyping was offered and declined prior to coverage of cfDNA testing for RhD/alloimmunization indications.

SourceLink

POLICY UPDATE CHANGES

01/01/2026, Summary of Changes = Template Update; created shared policy version to support application to Oxford plan membership; archived previous policy version 2025T0560JJ and MATERNITY 025.35.

1Medically Necessary Indication Group (RhD/alloimmunization)

5+Unproven/Not Medically Necessary Indication Examples Listed

8Specific Procedure Codes Listed

0.71%High-risk CNV detection rate in one large NIPT-plus study

38.42%Overall PPV for CNV detection (one study)

100%Reported sensitivity/specificity for some fetal antigen cfDNA analytic validation cohorts

Coverage Summary

Scope: UnitedHealthcare Commercial and Individual Exchange medical policy governing coverage and medical necessity criteria for cell-free fetal DNA (cfDNA / NIPT) testing during pregnancy, including RhD genotyping, fetal antigen testing, screening for common trisomies and sex chromosome aneuploidies, and expanded applications such as rare autosomal trisomies (RATs), microdeletions/CNVs, single-gene NIPT, and twin zygosity. Overview: The policy takes a mixed stance: cfDNA testing is medically necessary and supported for fetal RhD/blood group antigen genotyping in alloimmunized or at-risk pregnancies when specific criteria are met, while cfDNA applications beyond established aneuploidy screening (genome-wide/exome-wide panels, CNVs/RATs, and most single-gene or expanded panels) are considered unproven / not medically necessary because of insufficient evidence, variable performance, and low/uncertain positive predictive values; the policy also specifies documentation, pretest counseling, and diagnostic confirmation requirements and lists applicable codes and thresholds (e.g., gestational age performance and size-based CNV PPVs).

Key thresholds and quick facts

Gestational age for testingTesting may be offered as early as 9-10 weeks gestation for certain cfDNA assays (performance reported beginning at 9-11 weeks depending on assay)

CNV size performance noteIn one NIPT-plus study PPV differed by CNV size: >10 Mb PPV 46.5% vs ≤10 Mb PPV 28.57%

Fetal fraction no-call issueNo-call results frequently due to insufficient fetal fraction (FF); laboratories should validate FF limits and have pathways for no-call results

NT thresholdNuchal translucency (NT) ≥ 3.5 mm is a threshold to offer diagnostic testing and chromosomal microarray regardless of NIPT result

Policy number2026T0560KK

Effective dateJanuary 1, 2026

Medical Necessity Criteria

Coverage Rationale - Medically Necessary Indication (RhD/alloimmunization)

Cell-Free Fetal DNA testing using maternal plasma to determine fetal genotype is proven and medically necessary when the individual undergoing testing is alloimmunized or at risk for alloimmunization due to maternal RhD status or the presence of red cell antigen antibodies, and all of the following:

ALL of the following

Individual undergoing testing is alloimmunized OR at risk for alloimmunization due to maternal RhD status or presence of red cell antigen antibodies
Paternal genotyping shows heterozygosity for RhD OR paternal RhD status is unknown
Indicated invasive diagnostic testing (e.g., amniocentesis, chorionic villus sampling [CVS]) for fetal genotyping has been offered and declined

ref

General Guidance, Test Limitations, and Pretest Requirements

General guidance and test limitations

Professional society recommendations and general operational guidance:

ALL of the following

Positive NIPT/cfDNA screening results are not diagnostic and should be confirmed with diagnostic testing prior to pregnancy termination or irreversible decisions.
Expanded testing (genome-wide CNV detection, rare autosomal trisomies, microdeletions/duplications, single-gene disorders) has insufficient evidence for routine population screening and is not recommended for population-based screening by multiple societies.
NIPT is the most accurate screening method for common autosomal aneuploidies (trisomy 21, 13, 18) in singleton pregnancies but false positives occur; counseling and follow-up diagnostic testing should be offered for high-risk results.

Coding

Listed CPT/PLA/HCPCS and Molecular Codes referencedmixed

0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies
0489U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2)
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA of blood in pregnant individuals known to be RhD negative
0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis, circulating cell-free fetal DNA in maternal blood
81479	Unlisted molecular pathology procedure

Provider Actions and Documentation Requirements

Documentation Required

Offer invasive diagnostic testing when indicated

Offer invasive diagnostic testing (e.g., amniocentesis, chorionic villus sampling) for definitive fetal genotyping. Document that invasive diagnostic testing was offered and the member declined prior to performing cfDNA testing when indicated.

Documentation Required

Paternal genotyping documentation

Document paternal genotyping results when relevant (e.g., to establish paternal heterozygosity for RhD or presence/absence of targeted pathogenic variants). Include dates and laboratory reports in the medical record.

Evidence Summary

Evidence summary: Multiple validation studies and systematic reviews support high analytic performance for fetal RhD and some antigen genotyping (e.g., Gilstrop et al. 2025 reported sensitivity 100%, specificity 99.3%, PPV 98.4% from ~9 weeks; Hayes and HTA reports corroborate reduced unnecessary anti‑D use but note low-to-moderate quality utility evidence). For expanded targets, evidence is mixed: systematic reviews/meta-analyses of RATs show very low pooled PPVs (confirmed-method PPV ~0.07–0.13 or pooled estimates up to ~11% with high heterogeneity), and cohort studies report many RAT positives due to placental mosaicism. CNV/expanded genome-wide results vary by platform and CNV size (one large NIPT-plus cohort reported CNV detection rate 0.71% and overall PPV 38.4%, with higher PPV for certain syndromes like 22q11.2 and for CNVs >10 Mb). Studies of 22q11.2 screening report variable performance (Dar et al.: sensitivity 75%, specificity 99.84%, PPV 23.7% with an updated algorithm improving PPV to 52.6%; Hammer et al.: 22 confirmed positives among 22 tested with PPV 100% in that subset but limited by selective confirmatory testing). Single-gene and sgNIPT approaches show promising assay-level performance in selected cohorts (e.g., Wynn et al. sgNIPT sensitivity ~96%, PPV ~50% in reflex carrier settings), but evidence is limited and small for clinical utility in general populations. Overall, professional societies recommend cfDNA for common trisomies and SCAs with diagnostic confirmation for positives, endorse cautious or conditional use for 22q11.2, and advise against routine population screening with genome-wide/CNV/RAT or single-gene expanded panels until further validation.

Select quantitative evidence metrics

NIPT-plus high-risk CNV detection rate0.71% (221/31,256) detected as high-risk in one large NIPT-plus cohort

Overall CNV PPV (NIPT-plus study)

Revision History

01/01/2026administrative

Administrative/template update; created shared policy version to support application to Oxford plan membership; archived prior policy versions 2025T0560JJ and MATERNITY 025.35.

Policy Summary

Payersierra health and life

PolicyCell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy (PDF) PDF Opens in new windowopens in a new tabopens in a new window

Policy CodePolicy 2026T0560KK

Change TypeTemplate Update; archived prior versions

Effective DateJanuary 1, 2026

Next Review Date

SourceLink

On This Page

ref_orginal_placeholder_name_should_be_ignored_by_consumer_xxx**ref**

ref_extra_removed_by_validator_should_be_exact_b1_0_replaced_here_with_ref_field_only_needed_in_output_but_preserved_exactly_as_requested_b1_0

ref_b1_0_should_equal_the_requested_ref_field_b1_0

ref_b1_0_actual_value_should_be_b1_0

ref_b1_0_final_sanitized_field_b1_0_should_be_present

ref_b1_0_value_final_replacement_b1_0_should_be_here

ref_b1_0_cleaned_for_schema_b1_0_should_equal_b1_0

ref_b1_0_field_redundant_noise_removed_b1_0

Not Medically Necessary / Unproven Indications

Due to insufficient evidence of efficacy, cfDNA testing using maternal plasma is considered unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosome aneuploidy. This includes but is not limited to:

ANY of the following

Testing for the sole purpose of determining Twin Zygosity
Genome-wide or exome-wide screening (e.g., MaterniT Genome)
Cell-Free Fetal DNA expanded panel testing (panels that include testing beyond trisomies 21, 18, 13, and sex chromosome aneuploidy)
Screening for microdeletions/microduplications/copy number variations (CNVs)
Screening for single gene disorders (e.g., Vistara, PreSeek)
Screening for fetal antigen status other than RhD

Fetal fraction is an important quality control metric; laboratories should validate limits of detection and 'no-call' thresholds; providers should have clinical pathways for 'no-call' results which may include detailed ultrasound, repeat NIPT, alternative screening, or diagnostic testing.

NIPT for sex chromosome aneuploidies (SCA) is sufficiently accurate to be offered alongside autosomal aneuploidy screening with specific pretest counseling and consent; expansion to report SCAs and microdeletions is not universally recommended.

Fetuses with ultrasound abnormalities, including nuchal translucency (NT) ≥ 3.5 mm, should be offered diagnostic testing and chromosomal microarray regardless of prior NIPT results.

Repeat cfDNA screening may be considered if an initial sample was drawn at an early gestational age or if sample characteristics raise concerns; however repeat sampling is not advised if ultrasound anomalies are present or if delay would compromise reproductive options.

ref_b2_0_should_be_b2_0_in_output_field_exact

ref_b2_0_finalizing_field_redundant_cleanup_needed_but_output_must_only_include_ref_key

Specific applications with limited/insufficient evidence

Society positions advising caution or insufficient data for routine use:

ANY of the following

Genome-wide cfDNA testing to detect copy number variants larger than microdeletion screening is not recommended by ACOG/SMFM due to lack of clinical validation and undetermined accuracy/false-positive rates.
Routine NIPT for rare autosomal trisomies (RATs), subchromosomal imbalances, and microdeletion/duplication syndromes lacks sufficient data for routine performance assessment; if offered, protocols for managing high-risk results and platform-specific counseling must be available.
Screening for single-gene disorders by cfDNA is emerging; professional guidance (ACOG practice advisory) notes limitations and recommends cautious application with appropriate counseling.

ref

title

ref_b2_1_must_equal_b2_1_here_in_output_exactly

ref_extra_cleanup_removed_but_ref_present_only_b2_1

ref_b2_1_final_value_b2_1

ref_b2_1_field_clean

Fetal RhD and blood group antigen genotyping

Guidance and evidence summary for fetal RhD genotype testing:

ALL of the following

High-throughput cfDNA testing for fetal RhD genotype can guide antenatal anti-D prophylaxis decisions and reduce unnecessary use of blood products when cost-effectiveness thresholds are met (per NICE DG25).
Recent validation and systematic review evidence cited supports fetal RHD and other antigen genotyping (C, c, E, K, Fya) performance in large cohorts.

Pretest requirements / recommended ultrasound

Imaging and timing considerations before NIPT:

ALL of the following

At least one early first trimester scan for dating, diagnosis of multiple pregnancy, and confirmation of fetal viability should be offered prior to performing NIPT.

cfDNA / NIPT analyzes placental-derived cell-free fetal DNA circulating in maternal plasma to screen for fetal aneuploidies and other genetic anomalies and may be offered from early gestation (tests available as early as 9–11 weeks or about 10 weeks depending on assay). These are screening tests and are not diagnostic; only invasive diagnostic testing (chorionic villus sampling or amniocentesis) can definitively diagnose fetal genetic conditions. Laboratories use different methodologies and quality metrics (including fetal fraction and no-call thresholds), so confirmatory diagnostic testing is required for positive screen results before irreversible management decisions.

Definitions: Aneuploidy — abnormal number of chromosomes (e.g., trisomy 21, 13, 18). Cell-Free Fetal DNA (cffDNA / cfDNA) — small placental DNA fragments circulating in maternal blood used for noninvasive prenatal screening. NIPT / NIPS — noninvasive prenatal testing/screening using cfDNA. CGH — comparative genomic hybridization for CNV detection. Twin zygosity — dizygotic vs monozygotic twin classification. WGS — whole genome sequencing. RATs — rare autosomal trisomies. CNV — copy number variant. PPV — positive predictive value. FF (Fetal fraction) — proportion of fetal cfDNA in maternal plasma. No-call — an uninterpretable laboratory result often due to low FF.

Documentation Required

Genetic counseling recommendation

Recommend genetic counseling prior to testing to ensure the patient understands the benefits, limitations, and possible outcomes of cfDNA screening and diagnostic testing.

Documentation Required

Confirmatory diagnostic testing after positive cfDNA screen

For any positive cfDNA screen result, confirmatory diagnostic testing (CVS or amniocentesis with diagnostic genetic analysis) should be offered and documented before making irreversible clinical decisions.

Documentation Required

Genetic counseling and ultrasound for positive or no-call results

For positive or indeterminate (no-call) cfDNA results, perform and document genetic counseling and consider targeted ultrasound evaluation as part of follow-up management.

Documentation Required

Pretest counseling on limitations

Provide pretest counseling that explains test limitations, including that cfDNA is a screening test (not diagnostic), potential false positives/negatives, and limited evidence for indications beyond common aneuploidies.

Denial Risk

Interpretation caution for expanded tests

Expanded cfDNA panels (e.g., genome-wide, microdeletions, single-gene disorders) have limited and insufficient evidence for many indications; exercise caution interpreting results and document medical necessity when used outside established indications.

Documentation Required

Fetal antigen cfDNA testing in alloimmunized pregnancies

In alloimmunized pregnancies or those at risk for alloimmunization, cfDNA fetal antigen testing (for RhD or other clinically indicated antigens) may be used when clinically appropriate; document maternal antibody status, paternal genotype (if available), and rationale for testing.

Documentation Required

Confirm diagnostic testing before irreversible decisions

Confirm diagnostic testing results before counseling about or proceeding with any irreversible clinical decisions (e.g., pregnancy termination) following a positive cfDNA screen.

Documentation Required

Pretest counseling and consent for expanded screening

Obtain explicit informed consent documenting that the patient understands the potential outcomes, limitations, and follow-up requirements for expanded cfDNA screening when offered.

Documentation Required

Management pathway for "no-call" results

Management pathway for "no-call" results: Document the no-call result and the probable cause (e.g., low fetal fraction, high maternal BMI, gestational age, vanishing twin, maternal chromosomal abnormalities). Repeat cfDNA testing may be considered if low fetal fraction is the likely cause and sufficient gestational age exists; document the rationale for repeat testing, timing, and expected limitations. If repeat cfDNA remains no-call or if clinical concern is high (e.g., abnormal ultrasound, high-risk screening results, or persistent alloimmunization risk), offer diagnostic testing (CVS or amniocentesis) and document that it was offered and whether it was accepted or declined. Ensure genetic counseling is provided for interpretation and next-step decision-making. Include all laboratory reports, counseling notes, and patient decision documentation in the medical record.

Document likely cause of no-call (e.g., low fetal fraction, maternal factors, vanishing twin)
Consider repeat cfDNA if low fetal fraction and appropriate gestational age; document timing and rationale
If repeat is no-call or clinical concern persists, offer diagnostic testing (CVS/amniocentesis) and document offer/outcome
Provide and document genetic counseling for no-call results and planned next steps

Documentation Required

Offer early first-trimester ultrasound prior to NIPT

Offer an early first-trimester ultrasound prior to NIPT when indicated to confirm gestational age, identify multiple gestation, or detect anomalies that may affect test performance or interpretation.

38.42% overall PPV for clinically significant CNVs

Dar et al. 22q11.2 sensitivitySensitivity 75% for 22q11.2 deletion detection (Dar et al.), updated algorithm improved performance

Dar et al. 22q11.2 PPVPPV 23.7% (overall) in Dar et al.; updated algorithm PPV reported 52.6%

Analytic validation reported for some antigen cohortsSome fetal antigen cfDNA analytic validation cohorts reported 100% sensitivity and specificity in validation/clinical concordance analyses